Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Transcript
How can we overcome the complexity of the US health care system and the barriers it presents for biosimilar adoption?
The US health care delivery model is really positioned to either support or create barriers to biosimilar adoption based on where we land in terms of the reimbursement models and the alignment of incentives.
So, where we see today, the alignment of incentives sometimes is not there to support biosimilars or just lower-cost alternatives. So, I would say this is much bigger than just biosimilars. It's truly the US health care delivery model. And what would be most influential into impacting this model to ensure lower-cost alternatives could succeed in the market comes from policy and advocacy. So, we see quite a bit of activity at the state level, as well as federal level, trying to tackle drug pricing in at least advocating for, for example, parity status for biosimilars and lower-cost alternatives so that providers and patients have the option to utilize these agents.
So, I think more and more around the policy front and advocacy front is going to be critical and will continue to occur to support the success of these products in the future.
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More